B. Sites and W. Consultés, pubmed http://www.fondation-arthritis.org http://www.bio-therapy.net http://www.das-score

G. Schett, L. Coates, Z. Ash, S. Finzel, and P. Conaghan, Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future, Arthritis Res Ther, vol.13, issue.1, p.4, 2011.

J. Braun and J. Sieper, Biological therapies in the spondyloarthritides--the current state, Rheumatology, vol.43, issue.9, pp.1072-84, 2004.
DOI : 10.1093/rheumatology/keh205

O. Maley, W. Achinstein, B. Shear, and M. , Action of bacterial polysaccharide on tumors. II. Damage of sarcoma 37 by serum of mice treated with serratia marcescens polysaccharide, and induced tolerance, J Nat Cancer Inst, vol.29, pp.1169-75, 1962.

E. Carswell, L. Old, R. Kassel, S. Green, N. Fiore et al., An endotoxin-induced serum factor that causes necrosis of tumors., Proceedings of the National Academy of Sciences, vol.72, issue.9, pp.3666-70, 1975.
DOI : 10.1073/pnas.72.9.3666

D. Pennica, G. Nedwin, J. Hayflick, P. Seeburg, R. Derynck et al., Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin, Nature, vol.249, issue.5996, pp.724-733, 1984.
DOI : 10.1038/312724a0

URL : http://hdl.handle.net/11858/00-001M-0000-0019-AF84-E

B. Aggarwal, W. Kohr, P. Hass, B. Moffat, S. Spencer et al., Human tumor necrosis factor. Production, purification, and characterization, J Biol Chem, vol.264, pp.17595-605, 1985.

W. Fiers, Precursor structures and structure-function analysis of TNF and lymphotoxin, Immunol Ser, vol.56, pp.79-92, 1992.

M. Kriegler, C. Perez, K. Defay, I. Albert, and S. Lu, A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF, Cell, vol.53, issue.1, pp.45-53, 1988.
DOI : 10.1016/0092-8674(88)90486-2

F. Lejeune, D. Liénard, M. Matter, and C. Rüegg, Efficiency of recombinant human TNF in human cancer therapy, Cancer Immun, vol.6, p.6, 2006.

T. Spies, G. Blanck, M. Bresnahan, J. Sands, and J. Strominger, A new cluster of genes within the human major histocompatibility complex, Science, vol.243, issue.4888, pp.214-221, 1989.
DOI : 10.1126/science.2911734

C. L. Holmes, J. A. Russell, and K. R. Walley, Genetic Polymorphisms in Sepsis and Septic Shock, Chest, vol.124, issue.3, pp.1103-1118, 2003.
DOI : 10.1378/chest.124.3.1103

T. Decker, M. Lohmann-matthes, and G. Gifford, Cell-associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages, J Immunol, vol.138, pp.957-62, 1987.

M. Cuturi, M. Murphy, M. Costa-giomi, R. Weinmann, B. Perussia et al., Independent regulation of tumor necrosis factor and lymphotoxin production by human peripheral blood lymphocytes, Journal of Experimental Medicine, vol.165, issue.6, pp.1581-94, 1987.
DOI : 10.1084/jem.165.6.1581

A. Lieberman, P. Pitha, H. Shin, and M. Shin, Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus., Proceedings of the National Academy of Sciences, vol.86, issue.16, pp.6348-52, 1989.
DOI : 10.1073/pnas.86.16.6348

P. Libby, J. Ordovas, K. Auger, A. Robbins, L. Birinyi et al., Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells, Am J Pathol, vol.124, pp.179-85, 1986.

S. Warner and P. Libby, Human vascular smooth muscle cells. Target for and source of tumor necrosis factor, J Immunol, vol.142, pp.100-109, 1989.

G. Shaw and R. Kamen, A conserved AU sequence from the 3??? untranslated region of GM-CSF mRNA mediates selective mRNA degradation, Cell, vol.46, issue.5, pp.659-67, 1986.
DOI : 10.1016/0092-8674(86)90341-7

H. Loetscher, Y. Pan, H. Lahm, R. Gentz, M. Brockhaus et al., Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor, Cell, vol.61, issue.2, pp.351-360, 1990.
DOI : 10.1016/0092-8674(90)90815-V

S. Erickson, F. De-sauvage, K. Kikly, K. Carver-moore, S. Pitts-meek et al., Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice, Nature, vol.83, issue.6506, pp.560-563, 1994.
DOI : 10.1038/349524a0

V. Goëb, P. Dieudé, O. Vittecoq, O. Mejjad, J. Ménard et al., Association between the TNFRII 196R allele and diagnosis of rheumatoid arthritis, Arthritis Res Ther, vol.7, pp.1056-62, 2005.

D. Aderka, H. Engelmann, Y. Maor, C. Brakebusch, and D. Wallach, Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors, Journal of Experimental Medicine, vol.175, issue.2, pp.323-332, 1992.
DOI : 10.1084/jem.175.2.323

J. Cavaillon, Tumor necrosis factor et lymphotoxines, p.313, 1996.

M. Shalaby, B. Aggarwal, E. Rinderknecht, L. Svedersky, B. Finkle et al., Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors, J Immunol, vol.135, pp.2069-73, 1985.

F. Torti, B. Dieckmann, B. Beutler, A. Cerami, and G. Ringold, A macrophage factor inhibits adipocyte gene expression: an in vitro model of cachexia, Science, vol.229, issue.4716, pp.867-876, 1985.
DOI : 10.1126/science.3839597

O. Shea, J. Ma, A. Lipsky, and P. , CYTOKINES AND AUTOIMMUNITY, Nature Reviews Immunology, vol.15, issue.1, pp.37-45, 2002.
DOI : 10.1006/cyto.1999.0609

F. Congy and T. S. Dénutrition, In Gériatrie : guide pratique, p.354, 1993.

A. Kaibara, A. Moshyedi, T. Auffenberg, A. Abouhamze, E. Copeland et al., Leptin produces anorexia and weight loss without inducing an acute phase response or protein wasting, Am J Physiol, vol.274, pp.1518-1543, 1998.

J. Morley, D. Thomas, and M. Wilson, Cachexia: pathophysiology and clinical relevance

D. Kontoyiannis, M. Pasparakis, T. T. Pizarro, F. Cominelli, and G. Kollias, Impaired On/Off Regulation of TNF Biosynthesis in Mice Lacking TNF AU-Rich Elements, Immunity, vol.10, issue.3, pp.387-398, 1999.
DOI : 10.1016/S1074-7613(00)80038-2

D. Aletaha, T. Neogi, A. Silman, J. Funovits, D. Felson et al., 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative, Arthritis & Rheumatism, vol.61, issue.Suppl 31, pp.2569-81, 2010.
DOI : 10.1002/art.27584

M. Fojtíková, T. Studýnková, J. Filková, M. Lacinová, Z. Gatterová et al., Elevated prolactin levels in patients with rheumatoid arthritis: association with disease activity and structural damage, Clin Exp Rheumatol, vol.28, pp.849-54, 2010.

J. Keffer, L. Probert, H. Cazlaris, . Georgopoulos, E. Kaslaris et al., Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis, The EMBO Journal, vol.10, pp.4025-4056, 1991.

A. Abeles and M. Pillinger, The role of the synovial fibroblast in rheumatoid arthritis: cartilage destruction and the regulation of matrix metalloproteinases, Bull NYU Hosp Jt Dis, vol.64, pp.20-24, 2006.

P. Lipsky, D. Van-der-heidje, . St, E. Clair, D. Furst et al., Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis, New England Journal of Medicine, vol.343, issue.22, pp.1594-602, 2000.
DOI : 10.1056/NEJM200011303432202

J. Smolen, C. Han, M. Bala, R. Maini, J. Kalden et al., Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: A detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study, Arthritis & Rheumatism, vol.39, issue.4, pp.1020-1050, 2005.
DOI : 10.1002/art.20982

J. Moll and V. Wright, New York clinical criteria for ankylosing spondylitis. A statistical evaluation., Annals of the Rheumatic Diseases, vol.32, issue.4, pp.354-63, 1973.
DOI : 10.1136/ard.32.4.354

J. Zochling, J. Brandt, and J. Braun, The current concept of spondyloarthritis with special emphasis on undifferentiated spondyloarthritis, Rheumatology, vol.44, issue.12, pp.1483-91, 2005.
DOI : 10.1093/rheumatology/kei047

D. Van-der-heijde and W. Maksymowych, Spondyloarthritis: state of the art and future perspectives, Annals of the Rheumatic Diseases, vol.69, issue.6, pp.949-54, 2010.
DOI : 10.1136/ard.2009.119529

D. Gladman, C. Antoni, P. Mease, D. Clegg, and P. Nash, Psoriatic arthritis: epidemiology, clinical features, course, and outcome, Annals of the Rheumatic Diseases, vol.64, issue.suppl_2, pp.14-17, 2005.
DOI : 10.1136/ard.2004.032482

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766874

W. Taylor, D. Gladman, P. Helliwell, A. Marchesoni, P. Mease et al., Classification criteria for psoriatic arthritis: Development of new criteria from a large international study, Arthritis & Rheumatism, vol.59, issue.8, pp.2665-73, 2006.
DOI : 10.1002/art.21972

L. Gossec, J. Smolen, C. Gaujoux-viala, Z. Ash, H. Marzo-ortega et al., European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies, Annals of the Rheumatic Diseases, vol.71, issue.1, pp.4-12, 2012.
DOI : 10.1136/annrheumdis-2011-200350

A. Rozières, A. Hennino, and J. Nicolas, Le TNF-?? dans la physiopathologie du psoriasis, Annales de Dermatologie et de V??n??r??ologie, vol.133, issue.2, pp.174-80, 2006.
DOI : 10.1016/S0151-9638(06)70873-0

F. Molinié, C. Gower-rousseau, T. Yzet, V. Merle, B. Grandbastien et al., Opposite evolution in incidence of Crohn's disease and ulcerative colitis in Northern France (1988-1999), Gut, vol.53, issue.6, pp.843-851, 1988.
DOI : 10.1136/gut.2003.025346

F. Carbonnel, P. Jantchou, E. Monnet, and J. Cosnes, Environmental risk factors in Crohn's disease and ulcerative colitis: an update, Gastroent??rologie Clinique et Biologique, vol.33, pp.145-57, 2009.
DOI : 10.1016/S0399-8320(09)73150-1

B. Calkins, A meta-analysis of the role of smoking in inflammatory bowel disease, Digestive Diseases and Sciences, vol.284, issue.12, pp.1841-54, 1989.
DOI : 10.1007/BF01536701

R. Andersson, G. Olaison, C. Tysk, and A. Ekbom, Appendectomy and Protection against Ulcerative Colitis, New England Journal of Medicine, vol.344, issue.11, pp.808-822, 2001.
DOI : 10.1056/NEJM200103153441104

V. Binder, Genetic epidemiology in inflammatory bowel disease Dig Dis, pp.351-356, 1998.

Y. Ogura, D. Bonen, N. Inohara, D. Nicolae, F. Chen et al., A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease, Nature, vol.411, issue.6837, pp.603-609, 2001.
DOI : 10.1038/35079114

J. Matricon, Immunopathogen??se des maladies inflammatoires chroniques de l???intestin, m??decine/sciences, vol.26, issue.4, pp.405-415, 2010.
DOI : 10.1051/medsci/2010264405

C. Williams, R. Panaccione, S. Ghosh, and K. Rioux, Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease, Therapeutic Advances in Gastroenterology, vol.27, issue.1, pp.237-285, 2011.
DOI : 10.1016/S0002-9343(02)01383-9

A. Bensussan, B. Bizzini, P. Pouletty, R. Gallo, and D. Zagury, Kinoids: a novel generation of specific immune therapy against cytokines, Med Sci, vol.24, pp.306-319, 2008.

G. Burmester and A. Pezzutto, Developpement et différenciation des lymphocytes B. In Atlas de poche d'immunologie, Ed Flammarion, vol.2008, pp.26-34

R. Schroff, K. Foon, S. Beatty, R. Oldham, A. Morgan et al., Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy, Cancer Res, vol.45, pp.879-85, 1985.

K. Imai and A. Takaoka, Comparing antibody and small-molecule therapies for cancer, Nature Reviews Cancer, vol.23, issue.9, pp.714-741, 2006.
DOI : 10.1038/nrc1913

P. Solal-celigny, Lymphomes folliculaires et anticorps monoclonaux, Médecine thérapeutique, vol.5, pp.467-72, 1999.

G. Thibault, C. , and N. , Mécanismes d'action. In Mécanismes d'action des anticorps monoclonaux thérapeutiques. Ed Potentiel d'action, pp.14-28

K. Papp, Clinical development of onercept, a tumor necrosis factor binding protein, in psoriasis, Current Medical Research and Opinion, vol.26, issue.10, pp.2287-300, 2010.
DOI : 10.1185/03007995.2010.507492

S. Group, A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis, J Rheumatol, vol.32, pp.2303-2313, 2005.

E. Rondon and R. Venkataraman, Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels, Critical Care, vol.9, issue.5, p.20, 2005.
DOI : 10.1186/cc3798

B. Scallon, A. Cai, N. Solowski, A. Rosenberg, X. Song et al., Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists, Journal of Pharmacology and Experimental Therapeutics, vol.301, issue.2, pp.418-444, 2002.
DOI : 10.1124/jpet.301.2.418

R. Maini and M. Feldmann, How does infliximab work in rheumatoid arthritis?, Arthritis Research, vol.4, issue.Suppl 2, pp.22-30, 2002.
DOI : 10.1186/ar549

A. Catrina, J. Lampa, S. Ernestam, E. Klint, J. Bratt et al., Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis, Rheumatology, vol.41, issue.5, pp.484-493, 2002.
DOI : 10.1093/rheumatology/41.5.484

A. Sparsa, Etanercept, Annales de Dermatologie et de V??n??r??ologie, vol.132, issue.11, pp.861-76, 2005.
DOI : 10.1016/S0151-9638(05)79505-3

URL : https://hal.archives-ouvertes.fr/hal-00452839

E. Kruithof, L. De-rycke, J. Roth, H. Mielants, F. Van-den-bosch et al., Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies, Arthritis & Rheumatism, vol.52, issue.12, pp.3898-909, 2005.
DOI : 10.1002/art.21426

W. Sandborn, S. Hanauer, S. Katz, M. Safdi, D. Wolf et al., Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial, Gastroenterology, vol.121, issue.5, pp.1088-94, 2001.
DOI : 10.1053/gast.2001.28674

L. Santora, Z. Kaymakcalan, P. Sakorafas, I. Krull, and K. Grant, Characterization of Noncovalent Complexes of Recombinant Human Monoclonal Antibody and Antigen Using Cation Exchange, Size Exclusion Chromatography, and BIAcore, Analytical Biochemistry, vol.299, issue.2, pp.119-148, 2001.
DOI : 10.1006/abio.2001.5380

A. Van-kuijk, J. Degroot, R. Koeman, N. Sakkee, D. Baeten et al., Soluble Biomarkers of Cartilage and Bone Metabolism in Early Proof of Concept Trials in Psoriatic Arthritis: Effects of Adalimumab Versus Placebo, PLoS ONE, vol.35, issue.10, p.12556, 2010.
DOI : 10.1371/journal.pone.0012556.s007

G. Van-assche, S. Vermeire, and P. Rutgeerts, Adalimumab in Crohn's disease, Biologics, vol.1, pp.355-65, 2007.

A. Moore and B. Richardson, Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis, Clin Cosmet Investig Dermatol, vol.3, pp.49-58, 2010.

A. Nesbitt, G. Fossati, M. Bergin, P. Stephens, S. Stephens et al., Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor ?? agents, Inflammatory Bowel Diseases, vol.13, issue.11, pp.1323-1355, 2007.
DOI : 10.1002/ibd.20225

P. Mease, Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety, Rheumatology, vol.50, issue.2, pp.261-70, 2011.
DOI : 10.1093/rheumatology/keq285

N. Goel, S. Stephens, and . Certolizumab-pegol, Certolizumab Pegol, mAbs, vol.58, issue.2, pp.137-184, 2010.
DOI : 10.1136/ard.2008.099218

W. Weger, Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents, British Journal of Pharmacology, vol.49, issue.2, pp.810-830, 2010.
DOI : 10.1111/j.1476-5381.2010.00702.x

A. Suryaprasad and T. Prindiville, The biology of TNF blockade, Autoimmunity Reviews, vol.2, issue.6, pp.346-57, 2003.
DOI : 10.1016/S1568-9972(03)00048-X

F. Breedveld, P. Emery, E. Keystone, K. Patel, D. Furst et al., Infliximab in active early rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.63, issue.2, pp.149-55, 2004.
DOI : 10.1136/ard.2003.013961

M. Fabris, B. Tolusso, D. Poi, E. Assaloni, R. Sinigaglia et al., Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis, J Rheumatol, vol.29, pp.1847-50, 2002.

B. Mugnier and J. Roudier, Factors predicting responsiveness to anti-TNF?? therapy in patients with rheumatoid arthritis: using biotherapies rationally, Joint Bone Spine, vol.71, issue.2, pp.91-95, 2004.
DOI : 10.1016/j.jbspin.2003.10.007

D. Yocum, Effective use of TNF antagonists, Arthritis Research & Therapy, vol.6, issue.Suppl 2, pp.24-30, 2004.
DOI : 10.1186/ar997

R. Van-vollenhoven, A. Harju, . Brannemark, and L. Klareskog, Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor ?? blockers can make sense, Annals of the Rheumatic Diseases, vol.62, issue.12, pp.1195-98, 2003.
DOI : 10.1136/ard.2003.009589

F. Conti, F. Ceccarelli, E. Marocchi, L. Magrini, F. Spinelli et al., Switching tumour necrosis factor ?? antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period, Annals of the Rheumatic Diseases, vol.66, issue.10, pp.1393-1400, 2007.
DOI : 10.1136/ard.2007.073569

E. Comas, M. , L. Alastruey, C. Fernandez-bañares, and F. , How Do We Manage Vaccinations in Patients with Inflammatory Bowel Disease?, Digestive Diseases, vol.27, issue.3, pp.370-374, 2009.
DOI : 10.1159/000228576

J. Harris and J. Keane, How tumour necrosis factor blockers interfere with tuberculosis immunity, Clinical & Experimental Immunology, vol.144, pp.1-9, 2010.
DOI : 10.1111/j.1365-2249.2010.04146.x

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940142

I. Ferkolj, How to improve the safety of biologic therapy in Crohn's disease, J Physiol Pharmacol, vol.60, pp.67-70, 2009.

W. Robinson, M. Genovese, and L. Moreland, Demyelinating and neurologic events reported in association with tumor necrosis factor ? antagonism: By what mechanisms could tumor necrosis factor ? antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?, Arthritis & Rheumatism, vol.174, issue.9, pp.1977-83, 2001.
DOI : 10.1002/1529-0131(200109)44:9<1977::AID-ART345>3.0.CO;2-6

S. Verstappen, Y. King, K. Watson, D. Symmons, K. Hyrich et al., Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register, Annals of the Rheumatic Diseases, vol.70, issue.5, pp.823-829, 2011.
DOI : 10.1136/ard.2010.140822

D. Vries, M. Wolbink, G. Stapel, S. , D. Vrieze et al., Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation, Annals of the Rheumatic Diseases, vol.66, issue.9, pp.1252-1256, 2007.
DOI : 10.1136/ard.2007.072397

A. Perdriger, Infliximab in the treatment of rheumatoid arthritis, Biologics: Targets & Therapy, vol.3, pp.183-91, 2009.
DOI : 10.2147/BTT.S3189

P. Gisondi, C. Cotena, G. Tessari, and G. Girolomoni, Anti-tumour necrosis factor-alpha therapy increase body weight in patients with chronic plaque psoriasis : a retrospective cohort study

K. Briot, P. Garnero, L. Henanff, A. Dougados, M. Roux et al., Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor ?? treatment, Annals of the Rheumatic Diseases, vol.64, issue.8, pp.1137-1177, 2005.
DOI : 10.1136/ard.2004.028670

K. Briot, L. Gossec, S. Kolta, M. Dougados, and C. Roux, Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor-alpha treatment, J Rheumatol, vol.35, pp.855-61, 2008.

S. Marcora, K. Chester, G. Mittal, A. Lemmey, and P. Maddison, Randomized phase 2 trial of anti tumour necrosis factor therapy for cachexia in patients with early rheumatoid arthritis, Am J Clin Nutr, vol.84, pp.1463-72, 2006.

N. Alcorn, A. Tierney, O. Wu, H. Gilmour, and R. Madhoc, Impact of anti-tumour necrosis factor therapy on the weight of patients with rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.69, issue.8, p.1571, 2010.
DOI : 10.1136/ard.2009.122424

R. Brown, D. Spina, S. Butt, and G. Summers, Long-term effects of anti-tumour necrosis factor therapy on weight in patients with rheumatoid arthritis, Clinical Rheumatology, vol.27, issue.5, pp.455-61, 2012.
DOI : 10.1007/s10067-011-1863-6

C. Antoni, G. Krueger, D. Vlam, K. Birbara, C. Beutler et al., Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial, Annals of the Rheumatic Diseases, vol.64, issue.8, pp.1150-1157, 2005.
DOI : 10.1136/ard.2004.032268

G. Wells, J. Becker, J. Teng, M. Dougados, M. Schiff et al., Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate, Annals of the Rheumatic Diseases, vol.68, issue.6, pp.954-60, 2009.
DOI : 10.1136/ard.2007.084459

P. Claudepierre, J. Sibilia, P. Goupille, R. Flipo, D. Wendling et al., Evaluation of a French version of the Bath Ankylosing Spondylitis Disease Activity Index in patients with spondyloarthropathy

A. Calin, S. Garrett, H. Whitelock, L. Kennedy, O. Hea et al., A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index, J Rheumatol, vol.21, pp.2281-2286, 1994.

K. Weybel, L. Loët, X. Dieu, B. Vittecoq, and O. , A 3 mg/kg starting dose of infliximab in active spondyloarthritis resistant to conventional treatments is efficient, safe and lowers costs, Joint Bone Spine, vol.78, pp.50-55, 2011.

D. Mozaffarian, T. Hao, E. Rimm, W. Willett, and F. Hu, Changes in Diet and Lifestyle and Long-Term Weight Gain in Women and Men, New England Journal of Medicine, vol.364, issue.25, pp.2392-404, 2011.
DOI : 10.1056/NEJMoa1014296

S. Marcora, F. Casanova, E. Williams, J. Jones, R. Elamanchi et al., Preliminary evidence for cachexia in patients with well-established ankylosing spondylitis, Rheumatology, vol.45, issue.11, pp.1385-1393, 2006.
DOI : 10.1093/rheumatology/kel127

J. Argilés, J. López-soriano, S. Busquets, and F. López-soriano, Journey from cachexia to obesity by TNF, FASEB J, vol.11, pp.743-51, 1997.